Matches in SemOpenAlex for { <https://semopenalex.org/work/W15666944> ?p ?o ?g. }
- W15666944 endingPage "22" @default.
- W15666944 startingPage "17" @default.
- W15666944 abstract "AIM To reveal prognostically significant factors affecting efficacy of glivek therapy in untreated (duration of the disease 6 months) patients with chronic myeloid leukemia (CML) in a chronic phase. MATERIAL AND METHODS A total of 338 patients (64 untreated and 274 pretreated) with a chronic-phase CML on glivek therapy entered the trial. RESULTS Five-year survival on glivek was high (89, 98 and 88% in untreated and pretreated patients, respectively). Incidence of transformation in the acceleration phase and blast crisis was low both in untreated and pretreated patients (1.6 and 11%, respectively) and correlated with the rate of a complete cytogenetic response (CCR). Untreated patients had no factors affecting treatment efficacy negatively, CCR probability was 96%. Blastemia, thrombocytosis and splenomegaly reduced CCR probability significantly in pretreated patients. Slow reduction of the tumor mass, late achievement of a complete hematological response and a cytogenetic response decreased probability of CCR. CONCLUSION Glivek is a drug of choice for patients with chronic-phase CML. High probability of CCR both in untreated and pretreated patients lowers the risk of the disease transformation into the phase of acceleration/blast crisis and raises overall survival in both groups." @default.
- W15666944 created "2016-06-24" @default.
- W15666944 creator A5000380203 @default.
- W15666944 creator A5000821453 @default.
- W15666944 creator A5003704696 @default.
- W15666944 creator A5005680021 @default.
- W15666944 creator A5008070792 @default.
- W15666944 creator A5013453000 @default.
- W15666944 creator A5013660036 @default.
- W15666944 creator A5014888965 @default.
- W15666944 creator A5016291914 @default.
- W15666944 creator A5023504658 @default.
- W15666944 creator A5025474241 @default.
- W15666944 creator A5026178049 @default.
- W15666944 creator A5026492648 @default.
- W15666944 creator A5028580789 @default.
- W15666944 creator A5033172985 @default.
- W15666944 creator A5036380449 @default.
- W15666944 creator A5039292022 @default.
- W15666944 creator A5040369059 @default.
- W15666944 creator A5041694642 @default.
- W15666944 creator A5043087817 @default.
- W15666944 creator A5044915220 @default.
- W15666944 creator A5050430312 @default.
- W15666944 creator A5050529329 @default.
- W15666944 creator A5050649896 @default.
- W15666944 creator A5052624610 @default.
- W15666944 creator A5060376906 @default.
- W15666944 creator A5063690483 @default.
- W15666944 creator A5066505570 @default.
- W15666944 creator A5071441297 @default.
- W15666944 creator A5072212873 @default.
- W15666944 creator A5072594166 @default.
- W15666944 creator A5076425027 @default.
- W15666944 creator A5078114201 @default.
- W15666944 creator A5083855111 @default.
- W15666944 date "2007-01-01" @default.
- W15666944 modified "2023-09-27" @default.
- W15666944 title "[Prognosis factors in imatinib mesilate therapy in patients with a chronic phase of Ph-positive chronic myeloid leukemia: data from a multicenter non-randomized trial in Russia]." @default.
- W15666944 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17926465" @default.
- W15666944 hasPublicationYear "2007" @default.
- W15666944 type Work @default.
- W15666944 sameAs 15666944 @default.
- W15666944 citedByCount "0" @default.
- W15666944 crossrefType "journal-article" @default.
- W15666944 hasAuthorship W15666944A5000380203 @default.
- W15666944 hasAuthorship W15666944A5000821453 @default.
- W15666944 hasAuthorship W15666944A5003704696 @default.
- W15666944 hasAuthorship W15666944A5005680021 @default.
- W15666944 hasAuthorship W15666944A5008070792 @default.
- W15666944 hasAuthorship W15666944A5013453000 @default.
- W15666944 hasAuthorship W15666944A5013660036 @default.
- W15666944 hasAuthorship W15666944A5014888965 @default.
- W15666944 hasAuthorship W15666944A5016291914 @default.
- W15666944 hasAuthorship W15666944A5023504658 @default.
- W15666944 hasAuthorship W15666944A5025474241 @default.
- W15666944 hasAuthorship W15666944A5026178049 @default.
- W15666944 hasAuthorship W15666944A5026492648 @default.
- W15666944 hasAuthorship W15666944A5028580789 @default.
- W15666944 hasAuthorship W15666944A5033172985 @default.
- W15666944 hasAuthorship W15666944A5036380449 @default.
- W15666944 hasAuthorship W15666944A5039292022 @default.
- W15666944 hasAuthorship W15666944A5040369059 @default.
- W15666944 hasAuthorship W15666944A5041694642 @default.
- W15666944 hasAuthorship W15666944A5043087817 @default.
- W15666944 hasAuthorship W15666944A5044915220 @default.
- W15666944 hasAuthorship W15666944A5050430312 @default.
- W15666944 hasAuthorship W15666944A5050529329 @default.
- W15666944 hasAuthorship W15666944A5050649896 @default.
- W15666944 hasAuthorship W15666944A5052624610 @default.
- W15666944 hasAuthorship W15666944A5060376906 @default.
- W15666944 hasAuthorship W15666944A5063690483 @default.
- W15666944 hasAuthorship W15666944A5066505570 @default.
- W15666944 hasAuthorship W15666944A5071441297 @default.
- W15666944 hasAuthorship W15666944A5072212873 @default.
- W15666944 hasAuthorship W15666944A5072594166 @default.
- W15666944 hasAuthorship W15666944A5076425027 @default.
- W15666944 hasAuthorship W15666944A5078114201 @default.
- W15666944 hasAuthorship W15666944A5083855111 @default.
- W15666944 hasConcept C120665830 @default.
- W15666944 hasConcept C121332964 @default.
- W15666944 hasConcept C126322002 @default.
- W15666944 hasConcept C168563851 @default.
- W15666944 hasConcept C2777583451 @default.
- W15666944 hasConcept C2778729363 @default.
- W15666944 hasConcept C2779788118 @default.
- W15666944 hasConcept C3019892230 @default.
- W15666944 hasConcept C61511704 @default.
- W15666944 hasConcept C71924100 @default.
- W15666944 hasConcept C89560881 @default.
- W15666944 hasConcept C90924648 @default.
- W15666944 hasConceptScore W15666944C120665830 @default.
- W15666944 hasConceptScore W15666944C121332964 @default.
- W15666944 hasConceptScore W15666944C126322002 @default.
- W15666944 hasConceptScore W15666944C168563851 @default.
- W15666944 hasConceptScore W15666944C2777583451 @default.
- W15666944 hasConceptScore W15666944C2778729363 @default.
- W15666944 hasConceptScore W15666944C2779788118 @default.